Welcome!

News Feed Item

/C O R R E C T I O N -- MitoQ Limited/

In the news release, Antioxidant Shows Promise in Supporting Treatment for Lou Gehrig's Disease, issued 24-Mar-2014 over PR Newswire, we are advised by the company that the source being attributed should be "The Center of Free Radical and Biomedical Research" rather than "MitoQ Limited"; and the headline should read "Antioxidant Shows Promise in Fight Against Lou Gehrig's Disease" rather than "Antioxidant Shows Promise in Supporting Treatment for Lou Gehrig's Disease" as originally issued inadvertently. The complete, corrected release follows:

Antioxidant Shows Promise in Fight Against Lou Gehrig's Disease

MONTEVIDEO, Uruguay, March 24, 2014 /PRNewswire/ -- Researchers at The Center of Free Radical and Biomedical Research at Facultad de Medicina, Universidad de la Republica in Uruguay today announced the discovery that the antioxidant MitoQ prolonged the lifespan and health-span of mice suffering from amyotrophic lateral sclerosis-like (ALS) disease, and successfully improved functional parameters related to muscular strength and reversed mitochondrial damage in nervous and muscle tissue. The study was published in the journal Free Radical Biology and Medicine and the findings of this study point to a positive direction for those suffering from ALS.

Rafael Radi, MD, PhD, headed a research study that found MitoQ was able to extend the lifespan of mice with ALS.

MitoQ is a mitochondria-targeted antioxidant created over a decade ago that reduces mitochondrial oxidative stress and, when administered to a mouse model of ALS, delayed the progression of the fatal neurodegenerative disease. Mitochondria are also known as cellular batteries and provide energy to cells.  

Commonly known as Lou Gehrig's or Motor Neuron disease, ALS is a disorder within the nerve cells of the brain and spinal cord that control voluntary muscle movement, and ultimately results in progressive paralysis and death. The results of this study show a promise that mitochondria-targeted antioxidants could potentially be of use for the treatment of ALS, a condition for which there is currently no cure.

"This study supports the role of mitochondrial dysfunction in the development and progression of ALS, which may allow for the development of more mitochondria-targeted therapies to fight this disease," said Rafael Radi, MD, PhD, Director of the Center and a key member of the study's research team. "We also found that MitoQ has beneficial effects in the murine model of ALS, which will likely lead to clinical trials using MitoQ with ALS patients and hopefully lead to extend the survival and improve the quality of life of ALS patients."

Researchers sought to decrease oxidative stress in mitochondria as a way to slow the death of motor neurons and disease progression within the ALS-induced mice. MitoQ works by accumulating inside the mitochondria and performing antioxidant activity, while allowing the molecule to act specifically at the site of free radical formation in the cells and efficiently reduce oxidative stress.

To conduct their study, scientists administered MitoQ to the mice's drinking water from a time when early symptoms of neurodegeneration had become evident. After 20 days of administration, MitoQ was detected in all tested tissues and the treatment had slowed the decline of mitochondrial function in both the spinal cord and the quadriceps muscles.

"MitoQ increased approximately 6% the survival of the treated mice," noted Patricia Cassina, MD, PhD, another key senior member of the research team. "This might seem small, but it's in the range of the best that other drugs have been able to achieve with this model in which the disease progression is extremely fast and there is a small window of opportunity to improve symptoms and survival." Radi noted that MitoQ administration also resulted in improved muscular strength as evaluated by functional tests performed in the animals.

An advantage of MitoQ is that it has been tested for safety in a variety of clinical human trials since its inception in the late 1990s. The Center of Free Radical and Biomedical Research is now evaluating the possibility of conducting clinical human trials specifically related to MitoQ and its effects on ALS patients.

Photo - http://photos.prnewswire.com/prnh/20140324/NY88535

SOURCE The Center of Free Radical and Biomedical Research

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
It is one thing to build single industrial IoT applications, but what will it take to build the Smart Cities and truly society changing applications of the future? The technology won’t be the problem, it will be the number of parties that need to work together and be aligned in their motivation to succeed. In his Day 2 Keynote at @ThingsExpo, Henrik Kenani Dahlgren, Portfolio Marketing Manager at Ericsson, discussed how to plan to cooperate, partner, and form lasting all-star teams to change the...
In his keynote at @ThingsExpo, Chris Matthieu, Director of IoT Engineering at Citrix and co-founder and CTO of Octoblu, focused on building an IoT platform and company. He provided a behind-the-scenes look at Octoblu’s platform, business, and pivots along the way (including the Citrix acquisition of Octoblu).
"delaPlex is a software development company. We do team-based outsourcing development," explained Mark Rivers, COO and Co-founder of delaPlex Software, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
In his session at 20th Cloud Expo, Mike Johnston, an infrastructure engineer at Supergiant.io, will discuss how to use Kubernetes to setup a SaaS infrastructure for your business. Mike Johnston is an infrastructure engineer at Supergiant.io with over 12 years of experience designing, deploying, and maintaining server and workstation infrastructure at all scales. He has experience with brick and mortar data centers as well as cloud providers like Digital Ocean, Amazon Web Services, and Rackspace....
SYS-CON Events announced today that CA Technologies has been named “Platinum Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY, and the 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. CA Technologies helps customers succeed in a future where every business – from apparel to energy – is being rewritten by software. From ...
"I think that everyone recognizes that for IoT to really realize its full potential and value that it is about creating ecosystems and marketplaces and that no single vendor is able to support what is required," explained Esmeralda Swartz, VP, Marketing Enterprise and Cloud at Ericsson, in this SYS-CON.tv interview at @ThingsExpo, held June 7-9, 2016, at the Javits Center in New York City, NY.
SYS-CON Events announced today that Fusion, a leading provider of cloud services, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Fusion, a leading provider of integrated cloud solutions to small, medium and large businesses, is the industry’s single source for the cloud. Fusion’s advanced, proprietary cloud service platform enables the integration of leading edge solutions in the cloud, including cloud...
The buzz continues for cloud, data analytics and the Internet of Things (IoT) and their collective impact across all industries. But a new conversation is emerging - how do companies use industry disruption and technology enablers to lead in markets undergoing change, uncertainty and ambiguity? Organizations of all sizes need to evolve and transform, often under massive pressure, as industry lines blur and merge and traditional business models are assaulted and turned upside down. In this new da...
In his keynote at 18th Cloud Expo, Andrew Keys, Co-Founder of ConsenSys Enterprise, provided an overview of the evolution of the Internet and the Database and the future of their combination – the Blockchain. Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life settle...
SYS-CON Events announced today that Cloud Academy will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Cloud Academy is the industry’s most innovative, vendor-neutral cloud technology training platform. Cloud Academy provides continuous learning solutions for individuals and enterprise teams for Amazon Web Services, Microsoft Azure, Google Cloud Platform, and the most popular cloud computing technologies. Ge...
The best way to leverage your Cloud Expo presence as a sponsor and exhibitor is to plan your news announcements around our events. The press covering Cloud Expo and @ThingsExpo will have access to these releases and will amplify your news announcements. More than two dozen Cloud companies either set deals at our shows or have announced their mergers and acquisitions at Cloud Expo. Product announcements during our show provide your company with the most reach through our targeted audiences.
Cloud Expo, Inc. has announced today that Andi Mann and Aruna Ravichandran have been named Co-Chairs of @DevOpsSummit at Cloud Expo 2017. The @DevOpsSummit at Cloud Expo New York will take place on June 6-8, 2017, at the Javits Center in New York City, New York, and @DevOpsSummit at Cloud Expo Silicon Valley will take place Oct. 31-Nov. 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
SYS-CON Events announced today that Outlyer, a monitoring service for DevOps and operations teams, has been named “Bronze Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Outlyer is a monitoring service for DevOps and Operations teams running Cloud, SaaS, Microservices and IoT deployments. Designed for today's dynamic environments that need beyond cloud-scale monitoring, we make monitoring effortless so you...
DevOps is being widely accepted (if not fully adopted) as essential in enterprise IT. But as Enterprise DevOps gains maturity, expands scope, and increases velocity, the need for data-driven decisions across teams becomes more acute. DevOps teams in any modern business must wrangle the ‘digital exhaust’ from the delivery toolchain, "pervasive" and "cognitive" computing, APIs and services, mobile devices and applications, the Internet of Things, and now even blockchain.
WebRTC is the future of browser-to-browser communications, and continues to make inroads into the traditional, difficult, plug-in web communications world. The 6th WebRTC Summit continues our tradition of delivering the latest and greatest presentations within the world of WebRTC. Topics include voice calling, video chat, P2P file sharing, and use cases that have already leveraged the power and convenience of WebRTC.